These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 6443368)

  • 1. Experimental assessment of the relative abuse liability of triazolam and pentobarbital.
    Roache JD; Griffiths RR
    NIDA Res Monogr; 1984; 55():106-10. PubMed ID: 6443368
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of triazolam and pentobarbital: performance impairment, subjective effects and abuse liability.
    Roache JD; Griffiths RR
    J Pharmacol Exp Ther; 1985 Jul; 234(1):120-33. PubMed ID: 2861282
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Relative abuse liability of GHB in humans: A comparison of psychomotor, subjective, and cognitive effects of supratherapeutic doses of triazolam, pentobarbital, and GHB.
    Carter LP; Richards BD; Mintzer MZ; Griffiths RR
    Neuropsychopharmacology; 2006 Nov; 31(11):2537-51. PubMed ID: 16880774
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-response evaluation of the amnestic effects of triazolam and pentobarbital in normal subjects.
    Kirk T; Roache JD; Griffiths RR
    J Clin Psychopharmacol; 1990 Jun; 10(3):160-7. PubMed ID: 2198294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative abuse liability of indiplon and triazolam in humans: a comparison of psychomotor, subjective, and cognitive effects.
    Carter LP; Griffiths RR; Suess PE; Casada JH; Wallace CL; Roache JD
    J Pharmacol Exp Ther; 2007 Aug; 322(2):749-59. PubMed ID: 17502431
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Zolpidem and triazolam in humans: behavioral effects and abuse liability.
    Evans SM; Griffiths RR
    NIDA Res Monogr; 1989; 95():431-2. PubMed ID: 2701312
    [No Abstract]   [Full Text] [Related]  

  • 7. Comparison of the behavioral effects and abuse liability of ethanol and pentobarbital in recreational sedative abusers.
    Guarino JJ; Roache JD; Kirk WT; Griffiths RR
    NIDA Res Monogr; 1989; 95():453-4. PubMed ID: 2701315
    [No Abstract]   [Full Text] [Related]  

  • 8. Comparative abuse liability and pharmacological effects of meprobamate, triazolam, and butabarbital.
    Zawertailo LA; Busto UE; Kaplan HL; Greenblatt DJ; Sellers EM
    J Clin Psychopharmacol; 2003 Jun; 23(3):269-80. PubMed ID: 12826989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ramelteon: a novel hypnotic lacking abuse liability and sedative adverse effects.
    Johnson MW; Suess PE; Griffiths RR
    Arch Gen Psychiatry; 2006 Oct; 63(10):1149-57. PubMed ID: 17015817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential effects of triazolam and ethanol on awareness, memory, and psychomotor performance.
    Roache JD; Cherek DR; Bennett RH; Schenkler JC; Cowan KA
    J Clin Psychopharmacol; 1993 Feb; 13(1):3-15. PubMed ID: 8486815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute effects of triazolam and lorazepam on human learning, performance and subject ratings.
    Rush CR; Higgins ST; Bickel WK; Hughes JR
    J Pharmacol Exp Ther; 1993 Mar; 264(3):1218-26. PubMed ID: 8450459
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abuse liability of triazolam: experimental measurements in animals and humans.
    Griffiths RR; Ator NA; Roache JD; Lamb RJ
    Psychopharmacol Ser; 1987; 3():83-7. PubMed ID: 3823094
    [No Abstract]   [Full Text] [Related]  

  • 13. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users.
    Abanades S; Farré M; Barral D; Torrens M; Closas N; Langohr K; Pastor A; de la Torre R
    J Clin Psychopharmacol; 2007 Dec; 27(6):625-38. PubMed ID: 18004131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative cognitive and psychomotor effects of single doses of Valeriana officianalis and triazolam in healthy volunteers.
    Hallam KT; Olver JS; McGrath C; Norman TR
    Hum Psychopharmacol; 2003 Dec; 18(8):619-25. PubMed ID: 14696021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tandospirone and alprazolam: comparison of behavioral effects and abuse liability in humans.
    Evans SM; Troisi JR; Griffiths RR
    J Pharmacol Exp Ther; 1994 Nov; 271(2):683-94. PubMed ID: 7965783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discriminative stimulus effects of zolpidem in pentobarbital-trained subjects: II. Comparison with triazolam and caffeine in humans.
    Rush CR; Madakasira S; Goldman NH; Woolverton WL; Rowlett JK
    J Pharmacol Exp Ther; 1997 Jan; 280(1):174-88. PubMed ID: 8996195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An abuse liability comparison of flunitrazepam and triazolam in sedative drug abusers.
    Mintzer MZ; Griffiths RR
    Behav Pharmacol; 2005 Nov; 16(7):579-84. PubMed ID: 16170235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the effects of zolpidem and triazolam on memory functions, psychomotor performances, and postural sway in healthy subjects.
    Berlin I; Warot D; Hergueta T; Molinier P; Bagot C; Puech AJ
    J Clin Psychopharmacol; 1993 Apr; 13(2):100-6. PubMed ID: 8463441
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design and pharmacodynamic evaluation of novel dual release formulations of triazolam.
    Smith RB; Kroboth PD; Folan MM; Kroboth FJ; Rosanske TW
    Int J Clin Pharmacol Ther Toxicol; 1993 Sep; 31(9):422-9. PubMed ID: 8225690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flunitrazepam and triazolam: a comparison of behavioral effects and abuse liability.
    Mintzer MZ; Griffiths RR
    Drug Alcohol Depend; 1998 Dec; 53(1):49-66. PubMed ID: 10933340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.